American Cannabis Co (AMMJ) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the filing for Q2 FY2024, filed Feb 11, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AMMJ SEC filings page.
American Cannabis Co (AMMJ) reported $2.5M in revenue for fiscal year 2023, down 86.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
FY2023 restored product-level profitability, but a sharply smaller sales base left overhead and liabilities dominating the business.
Gross margin recovered to42.1% from13.5% , yet operating margin fell to-155.5% from-3.2% . The business earned more on each sale, but its reduced scale could not absorb operating costs.
FY2023 liabilities reached
The cash conversion gap was unusually wide: operating cash flow was
Financial Health Signals
We do not publish a peer-relative financial health score for American Cannabis Co, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
American Cannabis Co scores -10.94, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $13.7M against total assets of $2.8M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
American Cannabis Co passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.
American Cannabis Co reported a net loss of $3.7M while operations used $43K of cash. With neither figure positive, the ratio between the two carries no quality signal.
American Cannabis Co reported an operating loss of $3.9M against $114K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
American Cannabis Co generated $432K in revenue in Q2 2024. This represents a decrease of 49.4% from the same quarter a year earlier. Against the prior quarter it is up 68.9%.
American Cannabis Co's EBITDA was -$497K in Q2 2024, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
American Cannabis Co reported a net loss of $636K in Q2 2024. This represents a decrease of 5471.3% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
American Cannabis Co held $3K in cash as of Q2 2024; no long-term debt figure is on record for that period.
Not reported for Q2 2024.
Not reported for Q2 2024.
Margins & Returns
American Cannabis Co's gross margin was -70.2% in Q2 2024, indicating the percentage of revenue retained after direct costs. This is down 113.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 111.5 percentage points.
Not shown for Q2 2024: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2024: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q2 2024.
Capital Allocation
None of these metrics is reported for Q2 2024.
AMMJ Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing | Q1'23Filing | Q4'22Filing | Q3'22Filing |
|---|---|---|---|---|---|---|---|---|
| Revenue | $432K-49.4% | $256K-64.1% | $311K-97.3% | $600K-71.8% | $853K-82.0% | $712K+14.9% | $11.3M+1458.7% | $2.1M+182.0% |
| Cost of Revenue | $735K+51.1% | $150K-65.6% | N/A | N/A | $486K-88.1% | $436K-3.6% | $9.9M+2129.8% | $1.9M+339.5% |
| Gross Profit | -$303K-182.7% | $106K-61.8% | $150K-89.8% | $249K-4.0% | $366K-42.8% | $277K+65.0% | $1.5M+416.6% | $259K-21.2% |
| SG&A Expenses | $254K-48.3% | $234K-67.3% | $219K-76.8% | $378K-44.5% | $491K-37.9% | $717K+11.1% | $943K+40.6% | $681K+17.1% |
| Operating Income | -$557Kn/m | -$129Kn/m | -$3.1M-657.3% | -$129Kn/m | -$132Kn/m | -$441Kn/m | $565Kn/m | -$478Kn/m |
| EBITDA | -$497Kn/m | -$57Kn/m | N/A | -$69Kn/m | -$72Kn/m | -$379Kn/m | N/A | -$437Kn/m |
| Interest Expense | $83K+152.1% | $7K-76.4% | N/A | N/A | $33K+79.5% | $32K+16.6% | N/A | N/A |
| Net Income | -$636K-5471.3% | -$133Kn/m | -$3.0M-754.3% | -$157Kn/m | $12Kn/m | -$522Kn/m | $457Kn/m | -$398Kn/m |
| EPS (Basic) | $0.00 | $0.00 | N/A | $0.00 | $0.00n/m | -$0.01n/m | N/A | $0.00n/m |
| EPS (Diluted) | $0.00 | N/A | N/A | N/A | $0.00 | N/A | N/A | N/A |
| Diluted Shares (Avg) | 186M | 86M | N/A | N/A | 86M | 86M | N/A | N/A |
Not reported in any period shown, so not listed: R&D Expenses, Income Tax.
AMMJ Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing | Q1'23Filing | Q4'22Filing | Q3'22Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.1M-52.3% | $2.6M-40.4% | $2.8M-38.7% | $4.2M-2.5% | $4.5M-7.4% | $4.4M-53.4% | $4.6M+9.3% | $4.3M-3.5% |
| Current Assets | $419K-57.3% | $818K-5.0% | $900K-12.0% | $803K-14.8% | $982K-33.1% | $861K-86.4% | $1.0M+0.8% | $943K-25.3% |
| Cash & Equivalents | $3K-97.0% | $10K-82.2% | $21K-82.1% | $9K-95.4% | $93K-89.4% | $56K-98.7% | $118K-82.5% | $192K-78.3% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $266K-47.7% | $670K+79.3% | $586K+66.1% | $518K+47.0% | $508K+81.4% | $374K+17.8% | $353K+26.7% | $352K+27.1% |
| Accounts Receivable | $137K-53.4% | $121K-66.0% | $234K-50.0% | $202K-22.1% | $293K+42.8% | $355K+33.9% | $469K+4045.6% | $260K+475.6% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | N/A | N/A | N/A | $1.3M-32.9% | $1.3M-32.9% | $1.3M-32.9% | $1.3M-32.9% | $2.0M+29.7% |
| Total Liabilities | $2.8M-6.8% | $2.8M-5.7% | $2.8M+4.3% | $2.8M-7.1% | $3.0M-6.2% | $2.9M-62.2% | $2.7M+28.9% | $3.0M+82.5% |
| Current Liabilities | $2.2M+1.3% | $2.2M-1.4% | $2.2M+3.3% | $2.1M-29.4% | $2.2M-29.1% | $2.2M-69.1% | $2.1M+8.8% | $2.9M+77.7% |
| Non-Current Liabilities | $561K-29.0% | $605K-18.4% | $660K+7.7% | $738K+687.1% | $790K+742.9% | $742K+12.0% | $613K+250.3% | $94K+1033.8% |
| Total Equity | -$636K-142.6% | -$131K-108.8% | $2K-99.9% | $1.3M+5.3% | $1.5M-9.8% | $1.5M-14.7% | $1.9M-11.8% | $1.3M-54.8% |
| Retained Earnings | -$14.5Mn/m | -$13.9Mn/m | -$13.7Mn/m | -$10.7Mn/m | -$10.5Mn/m | -$10.5Mn/m | -$10.1Mn/m | -$10.5Mn/m |
Not reported in any period shown, so not listed: Long-Term Debt.
AMMJ Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing | Q1'23Filing | Q4'22Filing | Q3'22Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $31K-17.3% | -$11Kn/m | $288Kn/m | -$159Kn/m | $37Kn/m | -$209K-105.9% | -$268Kn/m | -$578Kn/m |
| Depreciation & Amortization | $60K-0.2% | $72K+16.8% | N/A | $60K+47.3% | $60K+71.9% | $61K+63.5% | N/A | $41K-40.7% |
| Stock-Based Compensation | N/A | $0-100.0% | N/A | N/A | $8K-76.8% | $9K-70.7% | N/A | $56K+575.3% |
| Investing Cash Flow | N/A | N/A | -$2-100.0% | $0n/m | -$9n/m | -$39Kn/m | $12Kn/m | -$104K-406.1% |
| Financing Cash Flow | -$38Kn/m | $249-99.9% | -$246K-235.3% | $447Kn/m | -$950n/m | $187K+101.8% | $182K+39.5% | $0-100.0% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
AMMJ Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing | Q1'23Filing | Q4'22Filing | Q3'22Filing |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -70.2%-113.1pp | 41.3%+2.5pp | 48.3%+35.3pp | 41.5%+29.3pp | 43.0%+29.5pp | 38.8%+11.8pp | 13.0%-26.2pp | 12.2%-31.5pp |
| Operating Margin | -128.9% | -50.4%+11.5pp | -1011.8% | -21.6%+1.0pp | -15.5%-11.7pp | -61.9%+20.2pp | 5.0% | -22.5%+12.2pp |
| Net Margin | -147.3% | -51.8%+21.5pp | -961.8% | -26.2%-7.5pp | 1.4%+5.0pp | -73.3%+10.9pp | 4.0% | -18.7%+2.3pp |
| Return on Equity | N/A | N/A | -193092.1%-193116.5pp | -11.9%+19.8pp | 0.8%+11.1pp | -35.3%-5.2pp | 24.5%+61.8pp | -31.6%-25.9pp |
| Return on Assets | -30.0%-30.3pp | -5.0%+6.8pp | -105.8%-115.7pp | -3.8%+5.5pp | 0.3%+3.8pp | -11.8%-6.3pp | 9.9%+28.6pp | -9.3%-5.7pp |
| Current Ratio | 0.19-0.3x | 0.380.0x | 0.42-0.1x | 0.39+0.1x | 0.450.0x | 0.39-0.5x | 0.490.0x | 0.32-0.4x |
| Liabilities-to-Equity | N/A | N/A | 1824.21+1822.8x | 2.12-0.3x | 1.98+0.1x | 1.98-2.5x | 1.45+0.5x | 2.40+1.8x |
| Asset Turnover | 0.200.0x | 0.10-0.1x | 0.11-2.3x | 0.14-0.4x | 0.19-0.8x | 0.16+0.1x | 2.45+2.3x | 0.50+0.3x |
Not reported in any period shown, so not listed: Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: The current ratio is below 1.0 (0.42), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| American Cannabis Co AMMJ | FY2023 | $2.5M | -$3.7M | N/A | $74K | — |
| Kaival Brands Innvtns Grp KAVL | FY2025 | $485K | N/A | N/A | $346K | — |
| LFTD Partners Inc LIFD | FY2025 | $36.9M | -$24.9M | -67.3% | $1.6M | — |
| Charlies Holdings Inc CHUC | FY2025 | $20.9M | $4.5M | 21.5% | $32.3M | — |
Where American Cannabis Co Ranks
Frequently Asked Questions
American Cannabis Co (AMMJ) reported $2.5M in total revenue for fiscal year 2023. This represents a -86.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
American Cannabis Co (AMMJ) revenue declined by 86.8% year-over-year, from $18.8M to $2.5M in fiscal year 2023.
No, American Cannabis Co (AMMJ) reported a net loss of $3.7M in fiscal year 2023.
American Cannabis Co (AMMJ) had EBITDA of -$3.8M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
American Cannabis Co (AMMJ) had a gross margin of 42.1% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.
American Cannabis Co (AMMJ) has a return on equity of -236155.9% for fiscal year 2023, measuring how efficiently the company generates profit from shareholder equity.
American Cannabis Co (AMMJ) recorded an outflow of $82K in free cash flow during fiscal year 2023. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
American Cannabis Co (AMMJ) recorded an outflow of $43K in operating cash flow during fiscal year 2023, representing cash used by core business activities.
American Cannabis Co (AMMJ) had $2.8M in total assets as of fiscal year 2023, including both current and long-term assets.
American Cannabis Co (AMMJ) invested $39K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
American Cannabis Co (AMMJ) had a current ratio of 0.42 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.
American Cannabis Co (AMMJ) had a liabilities-to-equity ratio of 1824.21 as of fiscal year 2023, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2023, because the filing data we hold for that year carries no long-term debt figure.
American Cannabis Co (AMMJ) had a return on assets of -129.4% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
American Cannabis Co (AMMJ) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2024). The market capitalization is $74K as of Nov 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
American Cannabis Co (AMMJ) trades at 0.0x sales, its market capitalization divided by $1.6M revenue, trailing 12 months to June 30, 2024. The market capitalization is $74K as of Nov 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2023, American Cannabis Co (AMMJ) held $21K in cash, cash equivalents and investments, and reported an operating cash outflow of $43K over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
American Cannabis Co (AMMJ) has an Altman Z-Score of -10.94, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
American Cannabis Co (AMMJ) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
American Cannabis Co (AMMJ) reported a net loss of $3.7M while operations used $43K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
American Cannabis Co (AMMJ) reported an operating loss of $3.9M against $114K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.